Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
| Brand name | DIFLUPREDNATE |
| Generic name | DIFLUPREDNATE |
| Active ingredient(s) | DIFLUPREDNATE |
| Distributed by / for | CIPLA |
| NDC | 69097-341-35 |
| Full product label | Difluprednate Ophthalmic Emulsion, 0.05%, 5ml bottles, Rx only, Mfd. by: Cipla Ltd., India At M/S Indoco Remedies Limited., L-32, 33, 34, Verna Industrial area, Verna - Goa, 403722, India; Mfd. for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-341-35. |
| Recalling firm | CIPLA |
| Distribution | Nationwide in the USA |
| Quantity | 8,136 bottles |
| Recall initiated | 2022-07-14 |
| Report date | 2022-07-27 |
| Recall completed | 2023-11-27 |
| Recall number | D-1283-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗